<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>324</serviceExecutionTime><Drug id="60103"><DrugName>SIR-1076</DrugName><DrugSynonyms><Name><Value>antioxidants (topical, retinal oxidative stress), Sirion Therapeutics</Value></Name><Name><Value>SIR-1076</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1021452">Sirion Therapeutics Inc</CompanyOriginator><CompaniesSecondary><Company id="1021452">Sirion Therapeutics Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="60103" type="Drug"><TargetEntity id="476856" type="siDrug">SIR-1076</TargetEntity></SourceEntity><SourceEntity id="1021452" type="Company"><TargetEntity id="5000030061" type="organizationId">Sirion Therapeutics Inc</TargetEntity></SourceEntity><SourceEntity id="288" type="ciIndication"><TargetEntity id="10038923" type="MEDDRA"></TargetEntity><TargetEntity id="D012164" type="MeSH"></TargetEntity><TargetEntity id="-422908255" type="omicsDisease"></TargetEntity><TargetEntity id="794" type="siCondition"></TargetEntity><TargetEntity id="1944" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="74" type="Action"><TargetEntity id="778" type="Mechanism">Antioxidants</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="288">Retinopathy</Indication></IndicationsSecondary><ActionsSecondary><Action id="15128">Ophthalmological agent</Action><Action id="74">Antioxidant agent</Action></ActionsSecondary><Technologies><Technology id="659">Ophthalmic liquid formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>S1</Code><Name>OPHTHALMOLOGICALS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-29T06:41:41.000Z</LastModificationDate><ChangeDateLast>2011-02-15T11:52:24.000Z</ChangeDateLast><AddedDate>2008-05-07T11:34:44.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1021452" linkType="Company"&gt;&lt;/ulink&gt;&lt;ulink linkID="1021452" linkType="Company"&gt;Sirion Therapeutics&lt;/ulink&gt; was investigating SIR-1076,  the lead compound from  a series of topical antioxidants, as an eye drop formulation for the potential treatment of oxidative stress associated retinal diseases, including age-related macular degeneration (AMD) and retinitis pigmentosa. By early 2009, Sirion was planning to initially evaluate SIR-1076 for reducing the risk of dry and wet AMD; in March 2009, the company expected to initiate clinical studies for AMD by 2010, with potential FDA approval within six years [&lt;ulink linkID="996060" linkType="Reference"&gt;996060&lt;/ulink&gt;], [&lt;ulink linkID="996117" linkType="Reference"&gt;996117&lt;/ulink&gt;]. However, in June 2010, Sirion completed the sale of several of its assets and ceased trading; development of SIR-1076 was presumed to have been discontinued [&lt;ulink linkID="1105580" linkType="Reference"&gt;1105580&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By March 2009, SIR-1076 had been shown to reduce biomarkers of oxidative stress within the retina when administered in animals [&lt;ulink linkID="996117" linkType="Reference"&gt;996117&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2008, preclinical data were reported at the ARVO 2008 Annual Meeting in Fort Lauderdale, FL [&lt;ulink linkID="900129" linkType="Reference"&gt;900129&lt;/ulink&gt;],  [&lt;ulink linkID="997243" linkType="Reference"&gt;997243&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1021452">Sirion Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="288">Retinopathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2010-06-03T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1021452">Sirion Therapeutics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="288">Retinopathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-03-30T00:00:00.000Z</StatusDate><Source id="996060" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput>